Today's Healthcare Pulse
Abridge teams with Eli Lilly and Nvidia to expand AI scribe platform
Abridge announced a strategic investment from Eli Lilly and a partnership with Nvidia to build a foundation model for clinical conversations. The collaboration aims to broaden Abridge’s AI‑scribe services across more health systems and integrate with payers. The company already supports over 300 health systems.
Also developing:
GLP-1 Drugs Target the Roots of Dementia
A systematic review of 30 preclinical studies finds that GLP‑1 receptor agonists—particularly liraglutide, semaglutide, dulaglutide and exenatide—consistently reduce amyloid‑beta plaques and tau tangles, the hallmarks of Alzheimer’s disease. The drugs also appear to curb neuroinflammation and improve brain insulin signaling, suggesting a neuroprotective effect. Early human trials have shown metabolic benefits such as preserved brain glucose metabolism but have not yet demonstrated cognitive improvement. Researchers argue that these agents may be most effective as preventive treatments before dementia symptoms emerge.
Regenerative Medicine: Promise, Hype, and What Actually Works
Regenerative medicine spans stem cells, platelet‑rich plasma (PRP) and autologous conditioned serum (ACS), but not all modalities live up to hype. Dr. Thomas Buchheit emphasizes that stem‑cell injections rarely persist in tissue and mainly trigger immune‑mediated repair, while PRP and...
AI-Driven Synthetic Evolution Accelerates Biological Design
Evolution is the most powerful optimization algorithm ever run. It just takes billions of years. Researchers are now rewriting the code. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here:...
CDC Announces Salmonella Outbreak in 13 States Linked to Backyard Poultry.
The CDC has confirmed a multistate Salmonella outbreak linked to backyard poultry, affecting 34 people in 13 states, with 13 hospitalizations and no deaths reported. Healthy‑looking chickens and ducks can carry the bacteria, exposing owners and their families through direct...
Regeneron Approves Free Gene Therapy, Sparks Industry Precedent Worries
$REGN wins FDA approval for its gene therapy to treat a very rare genetic form of hearing loss. The company is giving away the therapy for free. OTOF-related hearing loss affects approx. 50 newborns per year, so really rare, but......
Tirzepatide Significantly Reduces Cardiovascular Risk in High-Risk Patients
Two recent real‑world studies demonstrate that tirzepatide, a dual GIP/GLP‑1 receptor agonist, markedly lowers cardiovascular risk in high‑risk patients. In a propensity‑matched cohort of 1,281 type‑2 diabetics undergoing percutaneous coronary intervention, tirzepatide reduced mortality by 62% and cut major adverse...
DEBATE Today: Trump’s Psychedelic Order
Rav Arora announced on X that two leading drug‑policy experts, Kevin Sabet and Matthew Johnson, will join his Illusionist podcast to debate President Trump’s newly issued executive order on psychedelics. The order, released in early April, directs federal agencies to accelerate...
STAT+: Legislatures in Colorado and Virginia Resist Moves to Constrain Drug Affordability Boards
Legislators in Virginia and Colorado pushed back against attempts to limit the authority of state drug‑affordability boards. In Virginia, the General Assembly voted unanimously to keep the original bills that would create a board with power to set price caps...
What Is the UK Biobank Project and What Are the Privacy Concerns Around It?
The UK Biobank, launched in 2003, has amassed genetic, clinical and lifestyle data from 500,000 volunteers, fueling thousands of research papers and AI tools that predict disease risk. In April 2026, de‑identified health records from the biobank were listed for...
Why Clinical Care Resilience Is a Top Priority in Healthcare
Healthcare leaders warn that cyber‑threats and system failures can cripple clinical operations, making care‑resilience a top priority. Recent ransomware incidents at Michigan Medicine, University of Vermont Health Network, and Children’s National illustrate the need for cross‑departmental planning and frequent security...
Medical Training Must Evolve Faster than Technology
The future of medicine is arriving faster than our training models are evolving. A student starting medical school in 2026 won’t earn their M.D. until 2030, and likely won’t finish residency or practice independently until 2033 or beyond. By then, the...
Labels, Language and Other Strategies to Improve Communication About Lower Grade Ductal Carcinoma in Situ: Integration of Findings From Theoretical...
A mixed‑methods study combined a theoretical review with patient interviews to pinpoint language that best supports women diagnosed with low‑grade ductal carcinoma in situ (DCIS). Using Communication Accommodation Theory, researchers mapped clinician‑patient interactions across five communication domains and uncovered a...
Hiltzik: A Judge Labels RFK Jr.'s Attack on Transgender Care 'Unlawful' And an Act of 'Cruelty'
Federal Judge Mustafa T. Kasubhai in Oregon struck down Robert F. Kennedy Jr.'s December 18 declaration that threatened to cut Medicaid and Medicare funding for hospitals offering gender‑affirming care to minors. The decision, part of a lawsuit filed by 19...
Roche Launches New Elevidys Trial to Address EU Rejection in Duchenne Therapy Bid
Roche has launched a new global phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, targeting ambulatory boys after the European Medicines Agency rejected its earlier submission. The study will enroll about 100 patients and compare Elevidys to...
25% of Chronic Pain Patients Show ADHD Traits
A University of Tokyo study of 958 Japanese adults with chronic pain found that roughly 25% exhibited significant ADHD traits, a rate 2.4 times higher than in the general population. The research shows that ADHD does not directly cause pain...
New ADC Yields Encouraging Clinical Benefit in Platinum-Resistant Ovarian Cancer
In a Phase I trial presented at AACR 2026, the investigational antibody‑drug conjugate QLS5132 demonstrated notable antitumor activity in patients with advanced platinum‑resistant ovarian cancer. Among 28 heavily pretreated participants, the overall objective response rate was 50% and disease control...
STAT+: Sanofi Research Priorities in Flux as New CEO Logs In
Sanofi’s new chief executive, Belén Garijo, assumes leadership amid questions about the French drugmaker’s research direction. The company recently intensified its immunology portfolio, but recent trial disappointments have dampened expectations. Garijo is expected to reassess R&D allocations, potentially shifting focus...
Senate Hearings Put RFK Jr.'s Vaccine Stance Under Fire as Cassidy Questions HHS Secretary
Health Secretary Robert F. Kennedy Jr. faced two Senate hearings chaired by Sen. Bill Cassidy, where he denied anti‑vaccine claims and defended a $1 billion NIH vaccine research push. Cassidy, a physician‑senator battling a Trump‑backed primary challenger, pressed Kennedy on vaccine...
Roche, Facing Biosimilar Threats, Puts Faith in New Cancer and Obesity Drugs
Roche said its emerging breast‑cancer pill giredestrant and a suite of obesity drugs could generate up to $9 billion in peak annual sales. First‑quarter sales rose 6% to 14.7 billion Swiss francs (≈$18.8 billion) but fell 5% on currency effects, and the company...
Molina Controls Costs in Q1 but Future Medicaid Spending in Doubt
Molina Health Care posted a $14 million Q1 profit, beating analyst forecasts, while its medical loss ratios improved to 92% in Medicaid and 89.9% in Medicare Advantage. The gains were offset by a 2% drop in overall membership, driven by stricter...
Feeling Stuck with MCAS because of Finances? Here’s What You Need to Know.
A recent MC360 survey revealed finances and lack of knowledgeable help as the top barriers for people with mast cell activation syndrome (MCAS). To address this, the MC360 Clinic rolled out three tiered services: a $299 Strategy Session, a $499...
Is This The Part Of Endometriosis Treatment We’ve Been Missing?
Endometriosis affects over 10% of women, yet pain severity often mismatches visible lesions. A Washington State University study led by Kanako Hayashi shows repeated menstrual cycles trigger neuroinflammation, sensitizing the brain’s pain pathways so pain persists even after lesion removal....
90% of Chinese Trial Participants Hear Better After Gene Therapy for Deafness
A Chinese clinical trial of an experimental gene therapy for congenital deafness reported that 90% of participants experienced significant hearing improvement, including whispers and normal conversation. The results, published in Nature, mark the most compelling early evidence for a potential...
Researchers Use Multi-Modality Imaging to Learn More About MINOCA
Researchers at NYU Langone Health used combined optical coherence tomography and cardiac MRI to uncover the underlying causes of myocardial infarction with nonobstructive coronary arteries (MINOCA) in a large mixed‑sex cohort. The multi‑modality approach identified a definitive cause in 79%...
Biossil Exits Stealth with $70 Million USD to Give Failed Medicines a Second Chance
Toronto‑based biotech Biossil has emerged from stealth after raising roughly $70 million in equity from investors including OpenAI and Founders Fund. The company leverages an AI platform to spot abandoned drug candidates, then licenses or purchases them to fast‑track development. It...
Almanac Health Launches with $10M to Scale Research-Validated Clinical AI for Point-of-Care Support
Almanac Health announced a $10 million seed round, bringing total funding to nearly $12 million, led by F‑Prime with participation from General Catalyst and Lightspeed Venture Partners. Founded by Stanford physician‑researcher Cyril Zakka, the company commercializes a retrieval‑augmented generation (RAG) system that...
Department of Justice Officially Reschedules Marijuana: What Truckers Need to Know
The U.S. Department of Justice officially moved state‑licensed marijuana from Schedule I to Schedule III, allowing only FDA‑approved products and those tied to state medical licenses to benefit. The change acknowledges medical value but does not legalize cannabis federally and leaves commercial...
Doctors Must Speak Up or Lose Public Influence
Brutal truth: MD/MS doctors are losing the internet to people with weekend certifications. You studied for 10–15 years. They studied lighting, scripting, and delivery. They talk confidently about gut health, hormones, heart, brain. You hv depth. They hv reach. Hot take: The biggest threat to MD/MS doctors...
NeuFluent Expands Innovation Ecosystem with New Intelligent Implants and Robotics Initiative
NeuFluent, a neuroscience venture studio, announced an "intelligent implants and robotics" initiative, expanding its portfolio beyond brain‑computer interfaces and AI‑driven drug development. The program is headed by Dr. Kevin Foley, a pioneer of minimally invasive spinal surgery and robotics, who...
Voices: Freda Mowad, M.S., CCC-SLP, Chief Strategy Officer, Focal Point Care
Focal Point Care, launched a year ago, consolidates three specialized firms—Guided Care (managed‑care contracting), QRM (in‑house rehab management) and Future Care Consultants (billing and back‑office services)—to offer skilled‑nursing operators a single source for clinical, operational and financial support. The integrated...
Do Older Adults Need Routine Colonoscopies Or Low Thyroid Drugs?
A new JAMA analysis of 90,000 veterans shows that routine colonoscopies after age 75 yield minimal cancer‑prevention benefit, with incidence under 1% and mortality differences negligible. A separate Dutch study of 360 seniors found that two‑thirds of patients on low‑dose...
Backed by Redesign Health, Gravity Rail Launches with $2.75M to Provide No-Code AI Operating System for Healthcare
Gravity Rail, backed by Redesign Health, launched with a $2.75 million seed round. The no‑code AI operating system lets healthcare teams build, certify, and run AI engagement workflows across voice, SMS, email and web without programming. Early adopters reported a 30%...
Drug Trials Snapshot: NUZOLVENCE
Entasis Therapeutics received FDA approval on Dec 12 2025 for NUZOLVENCE, a single‑dose oral granule treatment for uncomplicated urogenital gonorrhea in patients aged 12 and older. The approval is based on a phase 3, open‑label, non‑inferiority trial of 930 participants across five countries,...
FDA Approves 2 Implantable Heart Devices From Biotronik
The FDA has cleared Biotronik’s Acticor Sky and Rivacor Sky implantable cardioverter‑defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT‑D) systems, set to launch at the Heart Rhythm Society 2026 meeting. The devices introduce left bundle branch area pacing, single‑lead DX atrial sensing,...
Stäubli Launches TX2-60L MedX Ready Medical Robot
Stäubli Robotics unveiled the TX2‑60L MedX Ready, a compact six‑axis robot built for surgical and medical applications. The system features MedXguiding, an intuitive manual guidance interface, and is produced under an ISO 13485‑certified quality management system. Stäubli highlights its extensive validation...
GE HealthCare: First Patient Dosed in Trial for Manganese-Based MRI Contrast Agent
GE HealthCare announced that the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese‑based MRI contrast agent, mangaciclanol, at the Mayo Clinic. The agent has earned FDA Fast Track designation for adults and children aged two...
The NHS Cannot Solve Women’s Health Inequalities Alone
The UK government’s renewed Women’s Health Strategy promises to add a decade to healthy life expectancy in deprived areas and curb medical misogyny, but it largely ignores the social determinants that drive health outcomes. Evidence shows women are disproportionately affected...
The Agentforce Life Sciences Consultant Certification
Salesforce introduced the Certified Agentforce Life Sciences Consultant exam, a Spring ’26‑aligned credential that validates expertise in building AI‑driven, compliant solutions for pharma, biotech and MedTech firms. The 60‑question, 105‑minute test costs $200 (≈¥30,000) and requires a 62% passing score,...
Sanofi Posts Upbeat Sales as R&D Pressure Builds
Sanofi reported first‑quarter net sales of €10.5 billion (about $12.3 billion), a 6.2% rise that beat Wall Street forecasts, driven largely by a 31% jump in Dupixent revenue. The French group reaffirmed its 2026 outlook, expecting high‑single‑digit sales growth and earnings that...
In Pakistan’s Deadly Heat, Low-Cost Cooling Tools Offer a Lifeline for Pregnant Women
Researchers at Aga Khan University tested low‑cost cooling tools—canvas canopies, hand fans, damp cloths and reflective paint—in Karachi’s hottest districts. The interventions lowered indoor temperatures by 3‑4 °C (5‑7 °F), offering relief where electricity for AC or fans is unreliable. Pregnant women...
Tech Giants Converge on AI‑Biology at SynBioBeta 2026
Silicon Valley's biggest tech players aren't just watching synthetic biology from a distance. They're showing up in person. This year at @SynBioBeta 2026, delegations from @Amazon, @Google, @Apple, @OpenAI, @Anthropic, @NVIDIA, and others are coming to San Jose to see what's...
Affordable Housing Serves as Unrecognized Care Coordination Hub
This is a really important reframing. Affordable housing operators are already acting as de facto care coordinators, but without the infrastructure, funding, or recognition that #healthcare systems receive. https://t.co/NIe4JUGjLe
Zotatifin
Effector Therapeutics and Switzerland’s SJP Biotec have entered Phase 2 trials of zotatifin, an intravenous eIF4A inhibitor, in selected advanced solid tumors. The study targets cancers such as breast, lung and pancreatic that rely heavily on dysregulated protein translation. Early Phase 1...
Roche Bets on Cancer and Obesity Drugs Amid Biosimilar Pressure
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs https://t.co/IIt0INA9sI @ByJonGardner $RHHBY
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/n2tSuJXS5b
FTC Order in TruHeight Case Signals Scrutiny of Height Claims and Incentivized Reviews
The FTC issued an administrative order against TruHeight, finding its height‑increase claims for children unsubstantiated and its review practices deceptive. The agency required the company to back any health claims with competent, double‑blind clinical evidence and to stop incentivizing 5‑star...
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/VPIH8iphVP
Phase 3 Trial Tests Daratumumab Reg
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/xv1RlCv8gl
Sanofi Reports Strong Sales Amid Growing R&D Pressure
Sanofi posts upbeat sales as R&D pressure builds https://t.co/4WUccjXY5D by Kristin Jensen $SNY + 2% $REGN
Amazon Teams with Grow Therapy for Employee Mental Health
Whoa... The employer behavioral health wars are heating up! Amazon is partnering with Grow Therapy on EAP. 👇 https://t.co/jVDA2xBhsE